Yttrium-90 Labeled HuM195

N/A

Report date: 2025/10/20 14:38:40

Base Information

Drug NameYttrium-90 Labeled HuM195

Drug Alias NameY90 MOAB M19590Y-MOAB M195Yttrium Y 90 humanized monoclonal antibody M195

ClassificationRadiation-emitting products > Nuclides > Yttrium > 90YRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionMyeloid cell surface antigen CD33 modulators

TargetsMyeloid cell surface antigen CD33

Therapy Area/IndicationsMyelodysplastic SyndromesMyelodysplastic-Myeloproliferative DiseasesLeukemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesMemorial Sloan Kettering Cancer Center National Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesMemorial Sloan Kettering Cancer Center National Cancer Institute

Active IndicationsN/A

Inactive IndicationsMyelodysplastic SyndromesMyelodysplastic-Myeloproliferative DiseasesLeukemia

Other Information

ATC CodeN/A